AzTrials
AzTrials

DementiaC-FiND PaviaNCT06983119

Case-Finding for Neurocognitive Disorders in Pavia

A study testing Case-finding for Neurocognitive Disorders in people with Dementia and Mild Cognitive Impairment, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dementia, Mild Cognitive Impairment
What is being tested?
Case-finding for Neurocognitive Disorders
Could I receive a placebo?
No, everyone receives an active treatment
How many people
490 participants
Where
1 siteItaly
Study dates
11 Jul 2024to 31 Jul 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

For the Primary Outcome the inclusion criteria are:

  • Age 50 or older
  • Assessment conducted using GPcog/ACE-III depending on the setting
  • No prior diagnosis of cognitive decline
  • Ability to understand the study objectives and sign an informed consent

For the Primary Outcome the exclusion criteria are:

  • Age under 50
  • Presence of a diagnosis of cognitive decline
  • Limited knowledge of the Italian language

For the secondary outcome the inclusion criteria are:

Patient:

  • All patients/people who are included in one of the actions provided through the "Ricor-Dare" Project or who are attending a visit scheduled in the clinical-care pathway of the CDCD Fondazione Mondino Pavia or Lomellina;
  • Ability to understand the aims of the study and to sign an informed consent

Caregiver:

  • Age equal to or greater than 18 years
  • Informal caregiver of a family member with a suspected or confirmed diagnosis of dementia who is included in one of the actions provided through the "Ricor-Dare" project or who are attending a visit scheduled in the clinical-care pathway of the CDCD;
  • Acceptance of informed consent and voluntary participation in the study.

Healthcare professionals:

  • All healthcare and social healthcare professionals (GPs, pharmacists, nurses, nurses auxiliary) who practice in the cities of Pavia and Vigevano who participate in the project and agree to undergo assessments and training;
  • Acceptance of informed consent and voluntary participation in the study.

Fo the Secondary Outcome the exclusion criteria are:

Patient:

  • Inability to understand the aims of the study and to sign an informed consent

Caregiver:

  • Age under 18
  • Formal caregivers, i.e. any person who provides assistance to the patient in exchange for payment of a fee;
  • Caregivers with limited knowledge of the Italian language.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Nicola Allegri, PhD contact

0039 0381692413

nicola.allegri@mondino.it

Italy1 site, 1 recruiting
  • IRCCS National Neurological Institute "C. Mondino" Foundation

    Pavia, Pavia, 27100

    Nicola Allegri, PhD, 0039 0381692413, nicola.allegri@mondino.it

    Alessia Rosi, PhD, 0039 0381692413, alessia.rosi@mondino.it

    Recruiting

Other trials in Italy

About this study

Official title: OPENING OF A MEMORY CLINIC IN THE PROVINCE OF PAVIA: Evaluation of Case-finding Strategies and Care for People With Cognitive Decline and Their Caregivers.

Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. This research project addresses the global public health challenge posed by dementia, focusing on early detection and comprehensive care. The research evaluates the clinical, social, and healthcare impact of two dementia-related projects in Italy:

  1. the first "Ricor-Dare," aims to create an integrated network for identifying new cases of dementia or Mild Cognitive Impairment (MCI) and providing care to patients and caregivers;
  2. the second involves establishing a new Center for Cognitive Disorders and Dementia (CCDD) in an area previously lacking such services.
Read more

The primary goal of this study is to assess the effectiveness of case-finding strategies promoted by the "Ricor-Dare" project for the early detection of cognitive decline. Researchers will compare three different settings in which case-finding will be conducted: at the general practitioners' offices, at the Dementia Operations Center, and at Open Days for the general population. The aim is to measure how many individuals in these three settings are diagnosed with Mild Cognitive Impairment (MCI) or dementia, compared to those identified as potential cases through cognitive testing.

The secondary goal of the study is to assess the social, care, and prevention impact of the activities offered within the two projects. This includes evaluating the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. The study will also assess the role of the "Ricor-Dare" project in addressing the needs of patients, caregivers, and professionals, as well as the effectiveness of awareness-raising and training activities on dementia. Overall, the study aims to provide valuable insights into improving care for people with dementia and supporting their families and caregivers.

Read the detailed description

Dementia is currently one of the most urgent challenges that global public health must address, with a significant caregiving burden that deeply impacts families, communities, and healthcare systems. It is a key priority in healthcare and social care planning worldwide, with growing emphasis on early diagnosis and appropriate support throughout the course of the disease. According to the World Health Organization, more than 55 million people globally have been diagnosed with dementia, and this number is expected to rise to 139 million by 2050. In Italy, approximately one million people are affected by dementia, and around 900,000 have MCI, with more than three million people directly or indirectly involved in caregiving. However, in high-income countries, the proportion of diagnosed cases remains relatively low, with estimates suggesting that only 20-50% of documented cases are diagnosed in primary care settings. The province of Pavia has 539,239 inhabitants, with an estimated 11,300 individuals diagnosed with dementia and 9,000 with MCI. Consistent with international literature, the ratio of observed to expected cases of dementia and MCI suggests a significant underestimation. Timely diagnosis of the disease or risk of disease enables the person and their caregivers to make informed choices, plan for the future, and gain access to treatments that can help manage symptoms. Centers for Cognitive Disorders and Dementia (CCDD) are healthcare services that play a critical role in the management of dementia and cognitive disorders. Scientific evidence shows that timely access to a specialized cognitive assessment and diagnostic service can lead to better outcomes for individuals with cognitive decline and their families, and be cost-effective for the healthcare system. An accurate and timely diagnosis, support for individuals with dementia and their families, along with early intervention by a multidisciplinary team of healthcare professionals, can have a positive impact on maintaining functional abilities and delaying cognitive decline and institutionalization.

The overall goal of this study is to assess the social and health impact of various services and actions aimed at individuals with cognitive decline within two projects initiated in Italy, specifically in in the Pavia area located in northern Italy: the "Ricor-Dare: integrated territorial network for dementia" project and the opening of a new Cognitive Disorders and Dementia Center (CCDD) Lomellina by Fondazione Mondino in the city of Vigevano. Specifically, the primary goal of this study is to measure the effects of case-finding strategies for the timely detection of dementia in its prodromal or early stages across three different settings. The secondary aim of this study is to evaluate and monitor the social and care effects of the activities offered within the two projects, aimed at patients, caregivers, healthcare professionals, and the community, through a series of indicators reflecting social and health care. This objective will allow for the evaluation, through a set of indicators, of the impact of these complex social and health care, and social actions both on patients identified through case-finding activities and on patients attending the new CCDD Lomellina in the province of Pavia.

For the primary goal of this study, the investigators will evaluate the impact of different case-finding strategies in identifying patients with MCI or dementia. These strategies will be implemented across three different settings:

  1. General Practitioners (GPs) Offices: With their in-depth knowledge of their patients' medical histories, GPs play a crucial role in identifying those at risk of dementia or exhibiting cognitive symptoms. Using tools like the GP Cognitive Assessment of Cognition (GPcog), GPs can detect early signs of cognitive decline and refer patients for further evaluation at a CCDD. As part of the study, two annual conferences will be organized to train GPs on neurodegenerative diseases, dementia risk factors, and the GPcog. Patients scoring at the GPcog below 5 or in the borderline range (5-8) will be referred for a second-level neuropsychological evaluation at the CCDD. Additionally, a neuropsychologist will visit selected GP offices three times a year. During these visits, the neuropsychologist will conduct interviews, assess risk factors using the Lifestyle for BRAin health (LIBRA), and perform cognitive evaluations using the Addenbrooke's Cognitive Examination-III (ACE-III). Patients with below-normal or borderline ACE-III scores will be recommended for further CCDD evaluation. This initiative aims to enhance GPs' awareness of case-finding tools in their routine practice.
  2. Information desk of the Dementia Operations Center (COD): The COD information desk offers a free public service aimed at the early management of citizens reporting subjective cognitive disturbances that may indicate prodromal or early-stage dementia. The case-finding strategy at the COD involves enrolling all citizens who independently report subjective cognitive disturbances without a prior diagnosis of cognitive decline. Specifically, a neuropsychologist will conduct an interview to collect demographic and medical history information, as well as dementia risk factors through the LIBRA Index, and carry out a first-level neuropsychological assessment through the ACE-III. Those scoring below the norm or borderline will be recommended for further evaluation at the CCDD.
  3. Open Days: The Open Days are territorial initiatives for citizen designed for the early management of reports regarding subjective cognitive disturbances that could indicate prodromal or early-stage dementia. The case-finding strategy for Open Days involves organizing approximately two events per year, aimed at early detection of cognitive disturbances. During the Open Day, a neuropsychologist will conduct an interview to collect demographic and medical history information, as well as risk factors for dementia through the LIBRA Index, and perform a first-level neuropsychological assessment through the ACE-III. Those scoring below the norm or borderline will be recommended for further evaluation at the CCDD.

For the secondary goal of the study, the investigators will assess the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. Below a detailed description of the six secondary outcomes are presented:

  1. Explore the effect of the opening of a new CCDD. Assessing the role and contribution of the new CCDD in the management and care of individuals with dementia and MCI comparing data with other CCDDs in the Lombardy region. At the new CCDD, various diagnostic and care services are offered for patients with cognitive impairment. These include a neurological consultation to assess cognitive deterioration, followed by additional tests such as neuropsychological evaluations, neuroimaging, and advanced diagnostics at the Mondino Foundation. Multidisciplinary consultations, such as geriatrics and psychiatry, may also be recommended based on the neurologist's discretion. After the diagnostic process, patients and their families receive a joint consultation with a neurologist and psychologist to discuss the diagnosis and define a care plan. This care plan encompasses pharmacological treatments, including regular follow-ups for adjusting medications, and non-pharmacological treatments, such as individual or group cognitive stimulation. To evaluate the impact of the new CCDD's activity, data will be collected on the number of patients assessed, their diagnoses, and the services provided. An online questionnaire based on the National Survey on Cognitive Disorders and Dementia Centers will be administered to the CCDD Mondino Lomellina and Mondino Pavia to gather this data. The responses will be compared with previous survey results and regional benchmarks.
  2. Explore the experience of people with cognitive decline and their caregivers accessing the new CCDD to evaluate the social and healthcare impact of opening a new CCDD. This will provide insights into challenges and needs, helping improve support throughout the diagnostic and care process. To achieve this, two methods will be employed. The first involves administering tailored questionnaires to both patients with mild dementia or MCI and their caregivers after their first follow-up visit at the CCDD. The second method includes conducting an online focus group with at least 10 caregivers, providing an opportunity to discuss their experiences with the new clinical care setup.
  3. Evaluate the impact and effectiveness of diagnostic and care pathways specifically designed for caregivers, offered in the "Ricor-Dare" project and through routine clinical practice at the new CCDD. This action involves three phases: an initial evaluation (pre-test) of caregivers' burden (Zarit Burden Interview) and caregivers' preparedness to assess their perceived readiness to manage the physical and emotional needs of their loved ones (Caregiver Preparedness Scale), followed by tailored support interventions (individual psychological support, psychoeducational groups, Alzheimer's café), and a final evaluation (post-test) with the same questionnaires use in the pre-test session to assess the effectiveness of the interventions.
  4. Evaluate the social and healthcare impact of the "Dementia Operations Center (COD)" as a resource for people with dementia, caregivers, and healthcare and social-care professionals. The Dementia Operations Center (COD) is the central hub of the "Ricor-Dare" project. It serves as a key point of contact for dementia-related inquiries, facilitating early intervention by directing patients, caregivers, and healthcare professionals to the appropriate services within the territorial network. The COD receives referrals from healthcare providers such as general practitioners (GPs), hospitals, nursing homes, social services, and directly from patients, caregivers, or citizens. The initial contact is made via phone, and based on an analysis of the caller's needs, further physical consultations may be recommended at the COD's information desk. With a thorough mapping of the local healthcare and social service network, COD aims to meet the needs of patients, caregivers, and professionals by providing guidance on the best path for cognitive decline management. This includes assistance with the recommended pathway, non-pharmacological treatments, and caregiver support. The COD also provides information on local healthcare services, such as CCDD, nursing homes, home care, social services, and legal processes like disability procedures. The first contact with COD is through a phone number, answered by trained psychologists or staff. If necessary, callers are referred to the physical COD desk for further evaluation.
  5. Evaluate the impact of awareness and education activities on dementia. The goal is to promote social and cultural actions that improve inclusivity for people with dementia within the community. Awareness initiatives will be delivered through three annual events targeting citizens, third-sector personnel (e.g., police, firefighters), and middle and high school students.
  6. Evaluate the effectiveness of training activities for healthcare and social care professionals. The objective is to assess the effectiveness of these training programs in enhancing professionals' understanding of dementia and their attitudes toward patients and caregivers. The training, provided within the Cariplo "Welfare in Aging" project - "Ricor-Dare: Integrated Territorial Dementia Network," includes annual sessions led by experts, tailored to different roles (e.g., GPs, pharmacists, nurses, healthcare assistants). To measure the training's effectiveness, participants will complete the Dementia Knowledge-20 (DK-20) and the Approaches to Dementia Questionnaire (ADQ) before (T0) and after (T1) the training. Additionally, a survey will assess the perceived utility and relevance of the training content in clinical practice.
Being tested
Case-finding for Neurocognitive Disorders
Keywords
Case-finding, Dementia, Mild Cognitive Impairment, Memory Clinic, Center for Cognitive Disorders and Dementia, Non-pharmacological intervention, Caregiver, Burden
Medical subject headings
Dementia, Cognitive Dysfunction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Case-finding for Neurocognitive DisordersOther

    The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.

Study groups in NCT06983119
Study groupRoleWhat they receive
Detection of people reporting cognitive concernsOtherNot described
Receives: Other: Case-finding for Neurocognitive Disorders

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effects of the case-finding strategy for the early detection of dementia in its prodromal or initial stages.

    The number of individuals, from the three case-finding settings, diagnosed at the CCDD with Mild Cognitive Impairment (MCI) or dementia within 26 months following assessment at case-finding compared to the total number of people identified as positive cases through GPcog and/or ACE-III and assessed within the three different case-finding settings.

    Measured: Up to 26 months

Secondary outcomes (6)
  1. The impact of the new CCDD on clinical care in an area that previously lacked such services.

    Number of patients managed at the new CDCD during the study period, all of whom underwent a baseline neurological examination, a comprehensive neuropsychological assessment, and a follow-up neurological evaluation.

    Measured: Up to 26 months

  2. Patient and caregiver satisfaction with accessing the new CCDD.

    Number of completed satisfaction questionnaires from both patients and caregivers and their satisfaction regarding waiting times for the first medical appointments, satisfaction with the initial consultation, fulfillment of needs, and quality of services provided. For each item minimum score is 1 and maximum score is 5, where a higher score indicates higher satisfaction.

    Measured: Up to 26 months

  3. The impact of the diagnostic-care pathway for caregivers at CCDD and "Ricor-Dare" project.

    Number of caregivers who completed the initial and final assessments and received support interventions. The efficacy of these interventions is assessed by measuring changes in caregiver burden using the validated Zarit Burden Interview. The minimum score is 0 and the maximum score is 88, where a higher score indicates a greater caregiver burden.

    Measured: Up to 26 months

  4. The impact of the "Dementia Operations Center (COD)" pathway of the "Ricor-Dare" project.

    Number of requests received and successfully addressed through the Dementia Operations Center (COD) pathway of the 'Ricor-Dare' project.

    Measured: Up to 26 months

  5. The impact of education activities on dementia promoted by the "Ricor-Dare" project.

    Number of people reached.

    Measured: Up to 26 months

  6. Effectiveness of training activities for healthcare and social care professionals promoted by the "Ricor-Dare" project.

    Number of healthcare and social care professionals participating in the training activities. The efficacy of these training activities is assessed by measuring changes in knowledge by the validated Dementia Knowledge-20 questionnaire (DK-20). The minimum score is 0 and the maximum score is 11, where a higher score indicates a greater knowledge of dementia.

    Measured: Up to 26 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 May 2025
  2. Study start11 Jul 2024
  3. Primary completion31 Jul 2026 (estimated)
  4. Study completion31 Jul 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
490 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06983119
Sponsor's protocol ID
CDCD-RICORDARE_2024
Acronym
C-FiND Pavia
Status last verified
May 2025
First submitted
14 Apr 2025
Last updated
21 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Shanahan N, Orrell M, Schepers AK, Spector A. The development and evaluation of the DK-20: a knowledge of dementia measure. Int Psychogeriatr. 2013 Nov;25(11):1899-907. doi: 10.1017/S1041610213001142. Epub 2013 Aug 15.

    PubMed 23947900
  • Pucciarelli G, Savini S, Byun E, Simeone S, Barbaranelli C, Vela RJ, Alvaro R, Vellone E. Psychometric properties of the Caregiver Preparedness Scale in caregivers of stroke survivors. Heart Lung. 2014 Nov-Dec;43(6):555-60. doi: 10.1016/j.hrtlng.2014.08.004. Epub 2014 Sep 18.

    PubMed 25239706
  • Chattat R, Cortesi V, Izzicupo F, Del Re ML, Sgarbi C, Fabbo A, Bergonzini E. The Italian version of the Zarit Burden interview: a validation study. Int Psychogeriatr. 2011 Jun;23(5):797-805. doi: 10.1017/S1041610210002218. Epub 2010 Dec 16.

    PubMed 21205379
  • Pigliautile M, Chiesi F, Stablum F, Rossetti S, Primi C, Chiloiro D, Federici S, Mecocci P. Italian version and normative data of Addenbrooke's Cognitive Examination III. Int Psychogeriatr. 2019 Feb;31(2):241-249. doi: 10.1017/S104161021800073X. Epub 2018 Jul 19.

    PubMed 30021668
  • Franchini F, Musicco M, Ratto F, Storti G, Shofany J, Caltagirone C, Di Santo SG. The LIBRA Index in Relation to Cognitive Function, Functional Independence, and Psycho-Behavioral Symptoms in a Sample of Non-Institutionalized Seniors at Risk of Dementia. J Alzheimers Dis. 2019;72(3):717-731. doi: 10.3233/JAD-190495.

    PubMed 31640092
  • Pirani A, Brodaty H, Martini E, Zaccherini D, Neviani F, Neri M. The validation of the Italian version of the GPCOG (GPCOG-It): a contribution to cross-national implementation of a screening test for dementia in general practice. Int Psychogeriatr. 2010 Feb;22(1):82-90. doi: 10.1017/S104161020999113X. Epub 2009 Nov 6.

    PubMed 19891815
  • Banerjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. Int J Geriatr Psychiatry. 2009 Jul;24(7):748-54. doi: 10.1002/gps.2191.

    PubMed 19206079
  • Steiner GZ, Ee C, Dubois S, MacMillan F, George ES, McBride KA, Karamacoska D, McDonald K, Harley A, Abramov G, Andrews-Marney ER, Cave AE, Hohenberg MI. "We need a one-stop-shop": co-creating the model of care for a multidisciplinary memory clinic with community members, GPs, aged care workers, service providers, and policy-makers. BMC Geriatr. 2020 Feb 11;20(1):49. doi: 10.1186/s12877-019-1410-x.

    PubMed 32046657
  • Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013 Jan;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007.

    PubMed 23305823
  • Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, Andrews G, Brayne C, Matthews FE, Stephan BC, Lipton RB, Katz MJ, Ritchie K, Carriere I, Ancelin ML, Lam LC, Wong CH, Fung AW, Guaita A, Vaccaro R, Davin A, Ganguli M, Dodge H, Hughes T, Anstey KJ, Cherbuin N, Butterworth P, Ng TP, Gao Q, Reppermund S, Brodaty H, Schupf N, Manly J, Stern Y, Lobo A, Lopez-Anton R, Santabarbara J; Cohort Studies of Memory in an International Consortium (COSMIC). The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS One. 2015 Nov 5;10(11):e0142388. doi: 10.1371/journal.pone.0142388. eCollection 2015.

    PubMed 26539987
  • Bacigalupo I, Mayer F, Lacorte E, Di Pucchio A, Marzolini F, Canevelli M, Di Fiandra T, Vanacore N. A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. J Alzheimers Dis. 2018;66(4):1471-1481. doi: 10.3233/JAD-180416.

    PubMed 30412486

Questions about this trial

What is this clinical trial studying?

A study testing Case-finding for Neurocognitive Disorders in people with Dementia and Mild Cognitive Impairment, run by IRCCS National Neurological Institute "C. Mondino" Foundation at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Nicola Allegri, PhD (0039 0381692413, nicola.allegri@mondino.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effects of the case-finding strategy for the early detection of dementia in its prodromal or initial stages. (time frame: Up to 26 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06983119, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in